Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2011

View Archived Issues

Differential expression of SUMO proteins in CRC may modulate response to treatment

Smac mimetic JP-1201 enhances response to chemotherapy in models of pancreatic ductal carcinoma

Aptamer-siRNA chimera Ch A-1 shows potent activity in HIV-1-infected mice

Administration of insulin-like growth factor II can enhance memory

Chelsea Therapeutics to modify phase III Northera study

Thrombospondin-1 expression may predict response of peritoneal metastatic gastric cancer to taxanes

Partial PPAR-gamma agonist PAM-1616 shows promise in models of diabetes and obesity

Enrollment begins in phase II ICT-107 trial in glioblastoma multiforme

Marina Biotech and Debiopharm partner for RNAi-based bladder cancer therapy

Theratechnologies and Ferrer enter into agreement for tesamorelin in Europe

Servier presents new antagonists of dopamine D2 and/or D3 receptor

RXi Pharma begins development program of antiscarring agent RXI-109

Cortex Pharma's CX-1739 shows promise to treat sleep apnea

Novel orexin OX1 receptor antagonists disclosed

Endpoints met in phase II WBI-1001 trials in psoriasis and atopic dermatitis

New inhibitors claimed of cytokine production and mast cell degranulation

FDA awards EGEN grant for phase II EGEN-001 development in ovarian cancer

Apeiron acquires rights to hu14.18-IL2 from Merck KGaA

New inhibitors of Mdm2/p53 interaction patented

Shionogi-ViiV Healthcare initiates phase III trial of 572-Trii in HIV

Alsuma autoinjector launched in U.S. for migraine and cluster headaches

Enrollment complete in FREEDOM-M trial of treprostinil diethanolamine

Regorafenib receives FDA orphan drug status in gastrointestinal stromal tumors

Health Canada approves Vyvanse for ADHD in adolescents and adults

Pfizer and Takeda sign copromotion agreements for rheumatoid arthritis products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...